cphi-onlineJuly 31, 2017
Tag: CPhI , Annual Reports
The CPhI predictions foresaw advancement in QbD, continuous processing, and a dramatic rise in FDA warning letters.
CPhI Worldwide, organized by UBM, announces the 2017 expert panel for the highly anticipated CPhI Worldwide Annual Industry Report (5th edition), which will be released in two parts - part one in late summer and part two during CPhI Worldwide (24-26 October 2017 in Frankfurt). The report is a comprehensive and critically important publication that analyses key trends and innovations forecast by a panel of world-class experts.
Since this is the 5th edition, CPhI Worldwide has decided to look back at previous Annual Reports to see how accurate the predictions were. These included the expanded use of PAT, QbD, serialization, green chemistry and R&D improvements, as well as the rise of strategic relationships between pharma and CMOs (or CDMOs as they are now called). However, a potential hindrance to the industry was the predicted rise in the number of FDA warning letters.
The 2013 Annual Report forewarned of the rapid increase of FDA warning letters as a result of a tightening regulation environment and a lagging industry. This prediction proved entirely accurate with FDA warning letters tripling over the past few years, from 4882 in 2012 to 14,590 in 2016. Another bold prediction from the first report was an expected boom in pharmaceutical R&D and improvements in development cycles. Interestingly, this was true in 2014 and 2015, stellar years for New Molecular Entities (NMEs)) and Biologics License Applications (BLAs), with 41 and 45 FDA approvals, respectively. This increased productivity, however, dropped off significantly in the following years, with 22 in 2016 and a similar number anticipated for 2017.
As predicted, PAT, QbD and serialization have now become industry-wide practices that further ensure quality and efficiency. Another trend identified, is the implementation of continuous processing in both Big Pharma and CDMOs for APIs and finished products, and the use of these technologies is now increasing. In addition, both pharma and outsourcing providers were correctly anticipated by the reports to begin looking at green chemistry, route scouting and process improvements earlier in development to make less wasteful products and this has already begun taking shape across the industry.
CMOs were anticipated to grow in prominence across the industry, with strategic pharma partnerships proliferating. In the past 2 years, mega-mergers were expected to become more frequent amid the aggressive competition to become leading and full service providers. This is perhaps best highlighted by the recent deals struck between a number of CDMOs and pharma companies, as well as the purchase of Patheon by Thermo Fisher. In addition, Big Pharma has also set-up co-development deals with a number of companies, particularly to develop and commercialise biologics and biosimilars.
However, some of the first Annual Reports missed the pulse of the industry, expecting tighter regulations to have a consequential effect of decreasing the number of biotechs and small companies entering the market. In contrast, the biotech environment has significantly heated up in last couple of years, with the traditional hot spots in the US seeing growth as well as a rapid emergence of newer biotech hubs – particularly in China.
This year’s CPhI Annual Report features 12 experts that provide valuable insight on the current and future state of our industry, including manufacturing, R&D, regulations, biologics, PAT/QbD, and innovation, among many others.
The CPhI Expert Panel members for 2017 are
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: